Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

BioGaia AB Updates on Results on Lactobacillus Reuteri Protectis in Premature Infants


Monday, 17 Sep 2012 09:30am EDT 

BioGaia AB announced that a double-blind, placebo-controlled study of 80 colicky infants showed that the crying time was reduced among the infants supplemented by drops with the probiotic Lactobacillus reuteri Protectis compared with those in the placebo group. The quality of life for the parents and families were also improved in the probiotic group compared to the placebo group. The study was done by Ms. Hania Szajewska who is Professor and Chair of the Department of Pediatrics at the Medical University of Warsaw in Poland. The reduction in crying time confirm earlier studies with Lactobacillus reuteri Protectis in infants with colic, but further, and for the first time, the parents perception of the baby’s colic and the quality of life of the parents and the family have been measured. These parameters showed improvements in the probiotic group as compared with the placebo group. The new study also included colic diagnosed infants that were partially fed with formula, extending the findings of earlier studies, which were performed in exclusively breast-fed infants. 

Company Quote

189.0
0.5 +0.27%
11 Jul 2014